Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Horatiu Olteanu

Showing results (91-100 of 115) with videos related to

Pageof 12
Sort By:
Blood Cancer Journal|April 20, 2023
Utility of flow cytometry screening before MRD testing in multiple myelomaVandana Panakkal, Arjun Lakshman, Min Shi, et al.
Seminars in Arthritis and Rheumatism|July 25, 2025
Developing efficient predictive models for the diagnosis of VEXAS syndromeDaniel Montes, Andrew C Hanson, Hannah E Langenfeld, et al.
Cytometry. Part B, Clinical Cytometry|August 21, 2024
Flow cytometry assay modifications: Recommendations for method validation based on CLSI H62 guidelinesSara A Monaghan, Steven Eck, Silvia Bunting, et al.
Blood Cancer Journal|July 31, 2024
Real-life sensitivity of flow cytometry minimal residual disease assessment for plasma cell neoplasmsDragan Jevremovic, Min Shi, Pedro Horna, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|February 6, 2017
Allogeneic Hematopoietic Cell Transplantation for Aggressive NK Cell Leukemia. A Center for International Blood and Marrow Transplant Research AnalysisMehdi Hamadani, Abraham S Kanate, Alyssa DiGilio, et al.
Rheumatology (Oxford, England)|August 26, 2024
Acute kidney injury, an underrecognized feature of VEXAS syndromeKambiz Kalantari, Megan M Sullivan, Loren P Herrera Hernandez, et al.
Blood Advances|April 27, 2021
Clinical, molecular, and prognostic comparisons between CCUS and lower-risk MDS: a study of 187 molecularly annotated patientsMarissa Li, Moritz Binder, Terra Lasho, et al.
American Journal of Hematology|September 18, 2024
FDA IDE validation of multiple myeloma MRD test by flow cytometryDragan Jevremovic, Min Shi, Pedro Horna, et al.
Cytometry. Part B, Clinical Cytometry|January 10, 2022
Evaluation of multiple myeloma measurable residual disease by high sensitivity flow cytometry: An international harmonized approach for data analysisKah Teong Soh, Neil Came, Gregory E Otteson, et al.
American Journal of Hematology|November 20, 2022
Reduced intensity conditioning allogeneic hematopoietic stem cell transplantation in VEXAS syndrome: Data from a prospective series of patientsAbhishek A Mangaonkar, Kimberly J Langer, Terra L Lasho, et al.
Pageof 12

Showing results (91-100 of 115) with videos related to

Sort By:
Pageof 12
Blood Cancer Journal|April 20, 2023
Utility of flow cytometry screening before MRD testing in multiple myelomaVandana Panakkal, Arjun Lakshman, Min Shi, et al.
Seminars in Arthritis and Rheumatism|July 25, 2025
Developing efficient predictive models for the diagnosis of VEXAS syndromeDaniel Montes, Andrew C Hanson, Hannah E Langenfeld, et al.
Cytometry. Part B, Clinical Cytometry|August 21, 2024
Flow cytometry assay modifications: Recommendations for method validation based on CLSI H62 guidelinesSara A Monaghan, Steven Eck, Silvia Bunting, et al.
Blood Cancer Journal|July 31, 2024
Real-life sensitivity of flow cytometry minimal residual disease assessment for plasma cell neoplasmsDragan Jevremovic, Min Shi, Pedro Horna, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|February 6, 2017
Allogeneic Hematopoietic Cell Transplantation for Aggressive NK Cell Leukemia. A Center for International Blood and Marrow Transplant Research AnalysisMehdi Hamadani, Abraham S Kanate, Alyssa DiGilio, et al.
Rheumatology (Oxford, England)|August 26, 2024
Acute kidney injury, an underrecognized feature of VEXAS syndromeKambiz Kalantari, Megan M Sullivan, Loren P Herrera Hernandez, et al.
Blood Advances|April 27, 2021
Clinical, molecular, and prognostic comparisons between CCUS and lower-risk MDS: a study of 187 molecularly annotated patientsMarissa Li, Moritz Binder, Terra Lasho, et al.
American Journal of Hematology|September 18, 2024
FDA IDE validation of multiple myeloma MRD test by flow cytometryDragan Jevremovic, Min Shi, Pedro Horna, et al.
Cytometry. Part B, Clinical Cytometry|January 10, 2022
Evaluation of multiple myeloma measurable residual disease by high sensitivity flow cytometry: An international harmonized approach for data analysisKah Teong Soh, Neil Came, Gregory E Otteson, et al.
American Journal of Hematology|November 20, 2022
Reduced intensity conditioning allogeneic hematopoietic stem cell transplantation in VEXAS syndrome: Data from a prospective series of patientsAbhishek A Mangaonkar, Kimberly J Langer, Terra L Lasho, et al.
Pageof 12